clinical stage life sciences venture capital investor

Amaranth Medical Initiates Trial of Sub-100-Micron MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold

Amaranth Medical, a privately held medical device company, announced the initiation of a clinical study of the Company’s latest-generation MAGNITUDE™ sirolimus-eluting bioresorbable scaffold (BRS) scaffold, which has a strut thickness in the sub-100-micron range. Dr. Antonio Colombo, director of the Hemodynamics Division at Ospedale San Raffaele in Milan, Italy and Dr. Juan F. Granada, executiveContinue Reading

Amaranth Medical 9-Months Clinical and Imaging Results of the FORTITUDE Sirolimus-Eluting Bioresorbable Scaffold Presented at TCT

Amaranth Medical, a privately held medical device company, announced that a presentation of the 9-month clinical and imaging results from the company’s FORTITUDE® sirolimus-eluting bioresorbable scaffold (BRS) took place during the First Report Investigations session at the Transcatheter Cardiovascular Therapeutics (TCT) 2016 scientific symposium on Monday, October 31st. Dr. Antonio Colombo, co-principal investigator and directorContinue Reading

vBloc Institute Demonstrates Positive Clinical Success in Patients Struggling with Weight Loss as Compared to Pivotal FDA Trial with EnteroMedics vBloc(R) Therapy in Combination with vBloc(R) Achieve Program

EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced clinical success at the Bariatric Center at Sky Ridge Medical Center in Colorado, a vBloc Institute partner, where several vBloc procedures have been performed to date by Frank H. Chae, MD, FACS,Continue Reading

Takeda Initiates Global Phase 3 Clinical Trial (TIDES) of Dengue Vaccine Candidate (TAK-003)

Study to evaluate vaccine protection against all four strains of dengue virus, regardless of previous exposure. Takeda Pharmaceutical Company Limited, (“Takeda”) today announced that it has vaccinated the first subject in the Tetravalent Immunization against Dengue Efficacy Study (TIDES), a Phase 3 double-blind, randomized and placebo-controlled trial of its live-attenuated tetravalent dengue vaccine candidate (TAK-003).Continue Reading

EnteroMedics Announces Exclusive Federal Government Business Channel Sales Agreement with Academy Medical to Provide vBloc(R) Neurometabolic Therapy to US Department of Veterans Affairs Medical Facilities

EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced an exclusive federal government business channel sales agreement with Academy Medical, LLC to sell its vBloc® Neurometabolic Therapy to U.S. Department of Veterans Affairs (VA) medical facilities. Academy Medical is a certifiedContinue Reading

EnteroMedics Announces Publication of Results Showing Significantly Greater Weight Loss in vBloc® Patients with Moderate Obesity

— Data from the ReCharge Study Published in Obesity Surgery — EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced the publication of results from the Company’s ReCharge Study on the effect of vBloc® Neurometabolic Therapy in patients with moderate obesityContinue Reading

EnteroMedics Named One of Fast Company’s Top Ten Most Innovative Companies in Biotech for 2016

EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Fast Company has recognized EnteroMedics among the Top 10 Most Innovative Companies in Biotech for 2016. Dan Gladney, President and Chief Executive Officer of EnteroMedics, stated, “Having brought to market theContinue Reading

Winthrop-University Hospital Becomes First Employer in the U.S. to Cover Innovative Obesity Treatment vBloc Therapy

Winthrop-University Hospital and EnteroMedics Inc.announced today that Winthrop-University Hospital has become the first employer in the United States to add vBloc Neurometabolic Therapy as an included benefit for its nearly 8,000 eligible employees and their spouses. As a leader in the field of bariatric surgery, Winthrop-University Hospital recently made headlines as an innovator with vBlocContinue Reading